Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non–small-cell Lung Cancer-Reference-Cited by-同舟云学术

Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non–small-cell Lung Cancer

Published:2017-11 Issue:6 Volume:18 Page:e433-e439
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Yokota Hayato,Sato Kazuhiro,Okuda Yuji,Kobayashi Hiroyuki,Takeda Masahide,Asano Mariko,Ito Hiroshi,Miura Masatomo

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa);Siegel-Lakhai;Oncologist,2005

2. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets;Cohen;Clin Cancer Res,2004

3. Effect of sustained elevated gastric pH levels on gefitinib exposure;Tang;Clin Pharmacol Drug Dev,2017

4. Current trends in the pharmacotherapy for peptic ulcer disease;Hixson;Arch Intern Med,1992

5. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs;Jones;Gut,1987

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration;Cancer Treatment Reviews;2024-09

2. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II;Critical Reviews in Oncology/Hematology;2024-08

3. H2 antihistamines: May be useful for combination therapies in cancer?;Biochemical Pharmacology;2024-05

4. Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort study;Cancer Treatment and Research Communications;2024

5. Efficacy of antacids for cisplatin-induced gastrointestinal symptoms in the treatment of lung cancer;Int. Journal of Clinical Pharmacology and Therapeutics;2023-06-01